Peroxisome Proliferator-activated Receptor Gamma Concentrations in Newly Diagnosed Hypertension Patients and the Metabolic Effects of Olmesartan

Basit Öğe Kaydı
dc.contributor.authorAkyurek, Omer
dc.contributor.authorAkbal, Erdem
dc.contributor.authorGunes, Fahri
dc.contributor.authorAkyurek, Nesibe
dc.date.accessioned2024-02-23T14:02:08Z
dc.date.available2024-02-23T14:02:08Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractBackground and Aims. We undertook this study to investigate the effects of olmesartan treatment on PPAR-gamma (PPAR-gamma) concentrations and metabolic syndrome (MetS) components in hypertensive (HT) patients. Methods. The study included 46 newly diagnosed hypertensive patients and 30 healthy controls. All hypertensive patients were given 40 mg of olmesartan, and they were evaluated weekly in the first month and then twice weekly during follow-up visits. At the end of 3 months, MetS components were assessed and serum PPAR-gamma transcription factor concentrations were again measured. Results. MetS was noted in 80.4% of HT patients. Serum PPAR-gamma transcription factor concentration were significantly lower in those with HT compared with the controls (p = 0.005). PPAR-gamma concentrations of controls were 1.14-fold higher than hypertensive patients. HDL levels were significantly increased after treatment (p = 0.004), triglyceride, total cholesterol, fasting blood glucose (FBG), and LDL levels were significantly reduced (p <0.05). There was a tendency toward increased PPAR-gamma concentrations after treatment, but these were not statistically significant (p = 0.154). Conclusions. Olmesartan treatment was found to generate beneficial effects on MetS parameters in HT patients but did not produce any significant increases in serum PPAR-gamma transcription factor concentration. (C) 2014 IMSS. Published by Elsevier Inc.en_US
dc.identifier.doi10.1016/j.arcmed.2013.12.005
dc.identifier.endpage142en_US
dc.identifier.issn0188-4409
dc.identifier.issn1873-5487
dc.identifier.issue2en_US
dc.identifier.pmid24480732en_US
dc.identifier.scopus2-s2.0-84896846169en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage138en_US
dc.identifier.urihttps://doi.org/10.1016/j.arcmed.2013.12.005
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11604
dc.identifier.volume45en_US
dc.identifier.wosWOS:000333139100005en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofArchives Of Medical Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPeroxisome Proliferator-Activated Receptoren_US
dc.subjectOlmesartanen_US
dc.titlePeroxisome Proliferator-activated Receptor Gamma Concentrations in Newly Diagnosed Hypertension Patients and the Metabolic Effects of Olmesartanen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu